Krishnamurthy, Jairam http://orcid.org/0000-0003-0939-4184
Luo, Jingqin http://orcid.org/0000-0003-2759-3072
Suresh, Rama
Ademuyiwa, Foluso http://orcid.org/0000-0002-6766-2258
Rigden, Caron
Rearden, Timothy
Clifton, Katherine
Weilbaecher, Katherine
Frith, Ashley
Roshal, Anna
Tandra, Pavan K. http://orcid.org/0000-0001-5271-3748
Cherian, Mathew
Summa, Tracy
Haas, Brittney
Thomas, Shana
Hernandez-Aya, Leonel
Bergqvist, Mattias http://orcid.org/0000-0002-0093-9443
Peterson, Lindsey
Ma, Cynthia X. http://orcid.org/0000-0002-8156-7492
Funding for this research was provided by:
Pfizer (N/A)
St. Louis Men’s Group Against Cancer Alvin J Siteman Cancer Center
Article History
Received: 18 June 2021
Accepted: 7 February 2022
First Online: 21 March 2022
Competing interests
: J.K. holds consulting or advisory roles from Abbvie, Pfizer, Sanofi, Rigel, Guidepoint Global, Gerson Lehrman Group, and AstraZeneca. A.F. reports stock and ownership interests in Athenex and research funding from Menarini, Seagen, and Daiichi Sankyo/Lilly. M.B. is employed by Biovica Inc and has stock and ownership interests in Biovica Inc. C.M. holds consultant or advisory roles from Novartis, Seattle Genetics, Agendia, AstraZeneca, Athenex, Bayer HealthCare Pharmaceuticals, Biovica Inc, Eisai, Olaris Inc, Philips Electronics North America, Puma Biotechnology and Sanofi-Genzyme, in addition to, research funding from Pfizer and Puma Biotechnology. All authors not listed declare no potential conflicts of interest.